pharma · Renal Impairment · Urinary Tract Infection · SPRO
Spero Therapeutics
Spero Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker SPRO. Primary therapeutic focus areas include Renal Impairment, Urinary Tract Infection, complicated urinary tra
675 Massachusetts Ave, 14th Floor, Cambridge, MA 02139, US HQ
2013 Founded
45 Employees
Public company Type
SPRO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 675 Massachusetts Ave, 14th Floor, Cambridge, MA 02139, US
- Founded
- 2013
- Employees
- 45
- Programs
- 21
- Drugs
- 9
- Patents
- 16
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)
Phase 1 · small molecule · Renal Impairment
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) for Renal Impairment is a Phase 1 program (small_molecule) at Spero Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code SPR994-102
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Spero Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Renal Impairment
- Status
- completed
- Trials
- 1